Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

[1]  Y. Yamada,et al.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.

[2]  Peter Balter,et al.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2015, The Lancet. Oncology.

[3]  A. Clark,et al.  Estimating the mutation load in human genomes , 2015, Nature Reviews Genetics.

[4]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[5]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[6]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[7]  H. Kohrt,et al.  Current clinical trials testing combinations of immunotherapy and radiation. , 2015, Seminars in radiation oncology.

[8]  P. Lambin,et al.  Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects , 2014, Clinical Cancer Research.

[9]  Joe Y. Chang,et al.  Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. , 2014, JAMA surgery.

[10]  R. Timmerman,et al.  Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Crittenden,et al.  Ideal Timing of Immunotherapy With Radiation in Murine Tumor Models , 2014 .

[12]  N. Altorki,et al.  1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  David A. Palma,et al.  The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.

[14]  C. N. Coleman,et al.  Defining Molecular Signature of Pro-Immunogenic Radiotherapy Targets in Human Prostate Cancer Cells , 2014, Radiation research.

[15]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[16]  Antoni Ribas,et al.  Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.

[17]  M. Bernstein,et al.  Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. , 2014, Cancer biotherapy & radiopharmaceuticals.

[18]  J. Karbach,et al.  Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates , 2014, Cancer Immunology Research.

[19]  S. Ferrone,et al.  Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing , 2014 .

[20]  J. Waisman,et al.  HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers , 2014, Cancer Immunology, Immunotherapy.

[21]  S. Steinberg,et al.  Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer , 2013, Cancer Immunology Research.

[22]  Brady T. West,et al.  Ipilimumab and radiation therapy for melanoma brain metastases , 2013, Cancer medicine.

[23]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[24]  Joe Y. Chang,et al.  Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer , 2013, Cancer.

[25]  S. Ferrone,et al.  Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death , 2013, International journal of cancer.

[26]  C. June,et al.  Radiation and immunotherapy: a synergistic combination. , 2013, The Journal of clinical investigation.

[27]  James M. Galvin,et al.  RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. , 2013 .

[28]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[29]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[30]  S. Demaria,et al.  Radiation therapy to convert the tumor into an in situ vaccine. , 2012, International journal of radiation oncology, biology, physics.

[31]  E. Small,et al.  Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients , 2012, The Journal of Immunology.

[32]  Peter Balter,et al.  Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer , 2012, Radiation oncology.

[33]  M. Bernstein,et al.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer , 2012, Front. Oncol..

[34]  Suresh Senan,et al.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.

[35]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[36]  R. Johnstone,et al.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. , 2012, Cancer research.

[37]  W. Urba,et al.  Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses , 2012, Science Translational Medicine.

[38]  Andressa Ardiani,et al.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. , 2012, Seminars in oncology.

[39]  Dong Yu,et al.  An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy , 2012, PloS one.

[40]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[41]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[42]  J. Hodge,et al.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. , 2012, Cancer biotherapy & radiopharmaceuticals.

[43]  J. Higgins,et al.  Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses , 2011, Cancer Immunology, Immunotherapy.

[44]  L. Zitvogel,et al.  The dendritic cell-tumor cross-talk in cancer. , 2011, Current opinion in immunology.

[45]  S. Sakaguchi,et al.  Regulatory T cells in tumor immunity , 2010, International journal of cancer.

[46]  R. Mirimanoff,et al.  Radiotherapy Suppresses Angiogenesis in Mice through TGF-βRI/ALK5-Dependent Inhibition of Endothelial Cell Sprouting , 2010, PloS one.

[47]  D. Douek,et al.  Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection , 2010, Nature Medicine.

[48]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[49]  M. Bernstein,et al.  Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? , 2009, Molecular bioSystems.

[50]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[51]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[52]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[53]  H. Schreiber,et al.  The role of stroma in immune recognition and destruction of well-established solid tumors. , 2006, Current opinion in immunology.

[54]  S. Demaria,et al.  Combining radiotherapy and immunotherapy: a revived partnership. , 2005, International journal of radiation oncology, biology, physics.

[55]  S. Steinberg,et al.  Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma , 2005, The Journal of Immunology.

[56]  Robert C. Rose,et al.  Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.

[57]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  K. Iwamoto,et al.  A Sense of Danger from Radiation1 , 2004, Radiation research.

[59]  G. Sauter,et al.  Tissue Microarray Evaluation of Melanoma Antigen E (MAGE) Tumor-Associated Antigen Expression: Potential Indications for Specific Immunotherapy and Prognostic Relevance in Squamous Cell Lung Carcinoma , 2002, Annals of surgery.

[60]  E. J. Friedman.  Immune modulation by ionizing radiation and its implications for cancer immunotherapy. , 2002, Current pharmaceutical design.

[61]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[62]  J. Mulé,et al.  Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. , 2001, Cancer research.

[63]  J. Xiang,et al.  Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells , 2001, International journal of cancer.

[64]  Yao-Tseng Chen,et al.  Expression of MAGE‐antigens in normal tissues and cancer , 2000, International journal of cancer.

[65]  A. Melcher,et al.  Apoptosis or necrosis for tumor immunotherapy: what's in a name? , 1999, Journal of Molecular Medicine.